MX394479B - Composiciones para activación de nrf2 mejorada y sus métodos de uso. - Google Patents

Composiciones para activación de nrf2 mejorada y sus métodos de uso.

Info

Publication number
MX394479B
MX394479B MX2018002743A MX2018002743A MX394479B MX 394479 B MX394479 B MX 394479B MX 2018002743 A MX2018002743 A MX 2018002743A MX 2018002743 A MX2018002743 A MX 2018002743A MX 394479 B MX394479 B MX 394479B
Authority
MX
Mexico
Prior art keywords
compositions
methods
enhanced
nrf2 activation
phytochemicals
Prior art date
Application number
MX2018002743A
Other languages
English (en)
Spanish (es)
Other versions
MX2018002743A (es
Inventor
Brooks Michael Hybertson
Joe Milton Mccord
Original Assignee
Pathways Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathways Bioscience Llc filed Critical Pathways Bioscience Llc
Publication of MX2018002743A publication Critical patent/MX2018002743A/es
Publication of MX394479B publication Critical patent/MX394479B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2018002743A 2015-09-03 2016-09-02 Composiciones para activación de nrf2 mejorada y sus métodos de uso. MX394479B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214175P 2015-09-03 2015-09-03
US201662355810P 2016-06-28 2016-06-28
PCT/US2016/050292 WO2017041054A1 (en) 2015-09-03 2016-09-02 Compositions for improved nrf2 activation and methods of their use

Publications (2)

Publication Number Publication Date
MX2018002743A MX2018002743A (es) 2018-06-06
MX394479B true MX394479B (es) 2025-03-24

Family

ID=58188643

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002743A MX394479B (es) 2015-09-03 2016-09-02 Composiciones para activación de nrf2 mejorada y sus métodos de uso.
MX2022009446A MX2022009446A (es) 2015-09-03 2018-03-02 Composiciones para activacion de nrf2 mejorada y sus metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022009446A MX2022009446A (es) 2015-09-03 2018-03-02 Composiciones para activacion de nrf2 mejorada y sus metodos de uso.

Country Status (9)

Country Link
US (1) US11413269B2 (enExample)
JP (1) JP6901787B2 (enExample)
CN (2) CN120754114A (enExample)
CL (1) CL2018000573A1 (enExample)
CO (1) CO2018003454A2 (enExample)
HK (1) HK1256480A1 (enExample)
MX (2) MX394479B (enExample)
PE (1) PE20190380A1 (enExample)
WO (1) WO2017041054A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220354916A1 (en) * 2015-09-03 2022-11-10 Pathways Bioscience, Llc Compositions for improved nrf2 activation and methods of their use
US10993981B2 (en) * 2016-07-11 2021-05-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organiation (Aro), (Volcani Center) Compositions for treatment of follicular tonsillitis using an emulsion based on rosemary extract and oregano essential oil
CN110545831A (zh) * 2017-04-27 2019-12-06 帝斯曼知识产权资产管理有限公司 Withania somnifera提取物提供针对空气污染相关疾病的保护的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
US9265808B2 (en) * 2004-03-23 2016-02-23 Lifeline Nutraceuticals Corporation Compositions for alleviating inflammation and oxidative stress in a mammal
WO2006073042A1 (ja) * 2005-01-05 2006-07-13 Toagosei Co., Ltd. Ｎｒｆ２依存遺伝子の活性化剤
CN101460185A (zh) * 2006-04-03 2009-06-17 雀巢产品技术援助有限公司 用于促进骨生长和维持骨健康的营养组合物及与其有关的方法
US8142806B2 (en) 2008-03-10 2012-03-27 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
CN102164508B (zh) 2008-07-31 2015-04-01 嘉康利公司 具有增加的抗氧化活性的麝香葡萄组合物
JP2011057654A (ja) * 2009-09-14 2011-03-24 Iwate Univ メタボリックシンドローム治療又は予防薬、及び脂肪細胞分化抑制方法
CA2785581A1 (en) 2009-12-24 2011-06-30 Stanley Kubow Compositions and methods for preventing and treating diseases and environmentally induced health disorders
KR101254847B1 (ko) * 2010-05-27 2013-04-15 한림대학교 산학협력단 실리비닌(silibinin)을 포함하는 골다공증 치료 및 예방용 조성물
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
CN104540513B (zh) * 2012-01-16 2019-04-05 赫克托·德·杰休斯·维莱斯-里韦拉 用于治疗与关节疾病相关疼痛的植物组合物
JP2013209351A (ja) 2012-03-30 2013-10-10 Sunstar Inc 抗酸化機能亢進剤
US20140287071A1 (en) * 2013-01-17 2014-09-25 Lifevantage Corporation Veterinary supplements
WO2014151891A1 (en) * 2013-03-14 2014-09-25 Walley Darlene Topical products
AU2014291615B2 (en) * 2013-07-17 2019-09-26 Council Of Scientific & Industrial Research Pharmaceutical composition for the treatment of diminution of bone tissue
WO2016037971A1 (en) * 2014-09-08 2016-03-17 Bios Line S.P.A. Compositions comprising glucosinolates precursors of sulforaphane in combination with extracts of rosemary

Also Published As

Publication number Publication date
PE20190380A1 (es) 2019-03-08
HK1256480A1 (zh) 2019-09-27
CN108136209A (zh) 2018-06-08
JP2018529763A (ja) 2018-10-11
CN120754114A (zh) 2025-10-10
MX2018002743A (es) 2018-06-06
US20180250264A1 (en) 2018-09-06
US11413269B2 (en) 2022-08-16
MX2022009446A (es) 2022-09-05
JP6901787B2 (ja) 2021-07-14
CO2018003454A2 (es) 2018-08-31
WO2017041054A1 (en) 2017-03-09
CL2018000573A1 (es) 2019-01-11

Similar Documents

Publication Publication Date Title
CL2019000230A1 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos.
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX2018006240A (es) Composiciones que comprenden cepas bacterianas.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MX378686B (es) Composiciones que comprenden cepas bacterianas.
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
EP3380062A4 (en) Compositions for treating the hair
PL3484469T3 (pl) Kompozycje i sposoby do wzmacniania działania środków przeciwdrobnoustrojowych
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
MX2022009446A (es) Composiciones para activacion de nrf2 mejorada y sus metodos de uso.
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
MX383386B (es) Nuevos inhibidores de braf y uso de los mismos para el tratamiento de reacciones cutáneas.
MX2018007128A (es) Composiciones para barnices dentales y metodos para su elaboracion y uso.
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
BR112017019154A2 (pt) uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica
MX2017014128A (es) 2-tiopirimidinonas.